Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05759780 · ClinicalTrials.gov registry record · NA
OCT Vibrography for Biomechanical Properties of Tissues
A NA study of Skin Diseases and Gingival Diseases, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT05759780 is a NA study of Skin Diseases and Gingival Diseases that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 90 participants, below the 203-participant average among 14 other Skin Diseases trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05759780, a NA study of Skin Diseases and Gingival Diseases, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study is to develop OCT Vibrography (aka OCT elastography) as a novel tool for measuring biomechanical properties of human tissues in vivo.
Conditions Studied
Interventions
- DEVICE Optical imaging of the tissues
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-08-19 |
| Est. Completion | 2026-08-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05759780
The ClinicalTrials.gov registry entry for NCT05759780 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 14 other Skin Diseases trials with a reported enrollment target (56% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Skin Diseases appearing as the primary indexed condition, and to 1 intervention - of which Optical imaging of the tissues is the first listed.
NCT05759780 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05759780 about?
NCT05759780 is a clinical study titled "OCT Vibrography for Biomechanical Properties of Tissues". The overall goal of this study is to develop OCT Vibrography (aka OCT elastography) as a novel tool for measuring biomechanical properties of human tissues in vivo.
What is the current status of trial NCT05759780?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2023-08-19. Estimated completion is 2026-08-28.
What conditions does trial NCT05759780 study?
This clinical trial studies the following conditions: Skin Diseases, Gingival Diseases, Cornea.
What interventions are being tested in trial NCT05759780?
The interventions under investigation include: Optical imaging of the tissues (DEVICE).
Who is sponsoring clinical trial NCT05759780?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05759780 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Teledermatology on Health Services Outcomes in the Department of Veterans Affairs
COMPLETED · NA
-
Joovvin' for Your Skin Health Study
COMPLETED · NA
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
RECRUITING · Early Phase 1
-
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
RECRUITING · Phase 2
-
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.